Comparison of Glycemic Variability by Using Insulin Glargine and Insulin Degludec in Japanese Patients With Type 1 Diabetes, Monitored by Continuous Glucose Monitoring: A Preliminary Report

Hidetaka Hamasaki, Takaaki Nakayama, Arisa Yamaguchi, Sumie Moriyama, Hisayuki Katsuyama, Masafumi Kakei, Hidekatsu Yanai

Abstract


Background: Insulin degludec is a novel ultra-long-acting basal insulin, which is used clinically first in Japan. We aimed to study efficacy of insulin degludec compared with insulin glargine in patients with type 1 diabetes, by using continuous glucose monitoring (CGM).

Methods: Patients studied were 4 Japanese patients with type 1 diabetes treated by the basal-bolus insulin therapy. We studied the influences of switching from insulin glargine to insulin degludec on parameters for glycemic variability using CGM for consecutive three days. Parameters studied for glycemic variability include the 24 h mean glucose levels, standard deviation (SD) values of 24 h glucose levels, M-values, mean amplitude of glycemic excursions (MAGE) values, 24 h area under the glucose curve (AUC), time in hypoglycemia and time in hyperglycemia. We compared these CGM data using insulin glargine with those using insulin degludec.

Results: Although a statistically significant difference was not obtained, 24 h mean glucose levels, 24 h AUC, SD values of 24 h glucose levels, MAGE values and time in hyperglycemia were smaller in the insulin degludec treatment as compared with those in the insulin glargine treatment. M-values in the insulin degludec treatment were significantly smaller than those in the insulin glargine treatment. Although a significant difference was not observed in time in hypoglycemia, hypoglycemia was developed in the patient during the treatment using insulin degludec.

Conclusions: The present study showed that the switching from insulin glargine to insulin degludec as basal insulin improved glycemic variability in patients with type 1 diabetes. To our knowledge, this is the first to report efficacy of insulin degludec compared with insulin glargine in patients with type 1 diabetes by using CGM.




J Endocrinol Metab. 2013;3(6):138-146
doi: http://dx.doi.org/10.4021/jem193w


Keywords


Continuous glucose monitoring; Hypoglycemia; Insulin degludec; Insulin glargine; Type 1 diabetes

Full Text: HTML PDF
 

Browse  Journals  

     

Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 

 

 

 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.